Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

During the hearing, an official from Novo Nordisk will be questioned about the pricing they charge for Ozempic and ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Drug maker Novo Nordisk has landed in hot water in the UK over its promotional practices. Now RTÉ Investigates examines the company's links to medical experts in Ireland.

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

Novo Nordisk has today forecast another year of double-digit record sales and operating profit growth as it began easing restrictions on supply of its popular weight-loss drug Wegovy.

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...

COPENHAGEN (dpa-AFX) - Novo Nordisk (NVO) is broadening patient access to its FDA-approved weight management drug, Wegovy (semaglutide) 2.4 mg, through a new partnership with WeightWatchers starting ...